A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
María Pilar Sánchez, Juan Eduardo Megías‐Vericat, Rebeca Rodríguez‐Veiga, Susana Vives, Juan Bergua, Anna Torrent, Sara Suárez-Varela, Blanca Boluda, Joaquín Martínez‐López, Isabel Cano‐Ferri, Evelyn Acuña‐Cruz, Laura Torres-Miñana, Beatriz Martín-Herreros, Alfons Serrano, Amparo Sempere, Eva Barragán, Claudia Sargas, Miguel Á. Sanz, David Martínez‐Cuadrón, Pau Montesinos, on behalf of the PETHEMA group
Topics & Concepts
MedicineTolerabilityInternal medicineRefractory (planetary science)Adverse effectFlag (linear algebra)Myeloid leukemiaRegimenGastroenterologyTransplantationClinical trialSalvage therapyPhases of clinical researchSurgeryChemotherapyMathematicsPhysicsAstrobiologyAlgebra over a fieldPure mathematicsAcute Myeloid Leukemia ResearchNuclear Structure and FunctionRetinoids in leukemia and cellular processes